Loading organizations...
InVivium Capital is a venture capital firm based in Chicago, Illinois, specializing in healthcare and life sciences investments, particularly in biotechnology and medical devices. The firm aims to identify and support entrepreneurs developing transformative solutions designed to enhance value for patients, payers, providers, and the broader pharmaceutical, biotechnology, and medical technology industries. Operating primarily within the US, InVivium Capital also engages in opportunistic global investments, providing long-term capital and strategic partnerships. InVivium Capital launched its first fund in July 2023, which is currently in market. The firm's leadership includes Managing Partner Michael Liang, General Partner Amy Len Kobe, and Partner Christopher Cox. Michael Liang also joined the board of an unspecified biotech company in November 2023. Its business model centers on venture capital investing through managed funds.
InVivium Capital has 1 tracked investment across 1 company. The latest tracked deal is $25.0M Series A in Onchilles Pharma in November 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 7, 2025 | Onchilles Pharma | $25.0M Series A | — | Kennedy Lewis Investment Management, Lincoln Park Capital, Lyzz Capital, University OF Chicago Medicine |
